umeclidinium/vilanterol (Anoro Ellipta)
Jump to navigation
Jump to search
Introduction
FDA-approved recommended Dec 2013.[2]
Indications
- treatment of chronic obstructive pulmonary disease
Dosage
- 2 puffs once daily
Adverse effects
- use with caution in patients with cardovascular disease
- safe for patients with cardiovascular disease
- myocardial infarction < 1%, more common in 1st 3 weeks
- not a risk in postmarketing experience
- myocardial infarction < 1%, more common in 1st 3 weeks
- safe for patients with cardiovascular disease
- paradoxical bronchospasm
- acute narrow-angle glaucoma
- worsening of urinary retention
Mechanism of action
- combines long-acting antimuscarinic agent (umeclidinium) with a long-acting beta-agonist (vilanterol)
Notes
- cost 280/month (2014)
More general terms
Components
References
- ↑ Physician's First Watch, September 12, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
- ↑ 2.0 2.1 FDA News Release: Dec. 18, 2013 FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm379057.htm
- ↑ Prescriber's Letter 21(4): 2014 Inhalers for COPD Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300403&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Highlights of Prscribing Information Anora Ellipta (umeclidiniumb & vilanterol powder) for oral inalation https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF